The retrospective analysis drew on an institutional database of patients who had received first-time stereotactic radiosurgery for a single brain metastasis and subsequently underwent surgical resection of that same lesion, providing the gold standard of histopathological confirmation for what the imaging had shown. Thirty-six patients met the inclusion criteria. For each patient, the team manually measured tumor volumes before treatment and at three standardized post-treatment intervals: six weeks, three months, and six months. Rather than relying on a single measurement dimension, the investigators segmented three distinct tissue compartments on each scan: the contrast-enhancing volume, the FLAIR hyperintense volume, and the necrotic component. From these they derived two ratios intended to capture the relationship between edema and tumor burden, the FLAIR-to-enhancing ratio and the enhancing-to-necrotic ratio, and then modeled how each parameter evolved over time.

The volumetric data revealed a treatment effect that was real but incomplete. Mean enhancing volume declined by 28.5 percent from baseline at six weeks, 25.8 percent at three months, and 18.9 percent at six months, a pattern consistent with an initial radiosurgical response that partially attenuated over the follow-up window. The FLAIR volume followed a different and more revealing course: it fell by 16.9 percent at six weeks and 22.2 percent at three months, but then rebounded to nearly baseline, changing only 2.4 percent from the pretreatment measurement at six months. This divergence between the enhancing core and the surrounding hyperintensity is precisely why the authors argue that single-compartment assessment, the standard practice in most surveillance protocols, misses a substantial portion of the biological story unfolding after radiation.

Statistical analysis confirmed that the two compartments do not move independently. Percent changes in FLAIR volume and enhancing volume correlated significantly at both the six-week time point, with a p-value of 0.004, and the three-month time point, where the association was even stronger at p less than 0.001. In practical terms, lesions whose enhancing cores were shrinking tended to show shrinking edema as well, at least in the early post-treatment period. But the correlation broke down in the cohort’s most clinically important subgroup: the patients whose lesions ultimately failed treatment and required resection. When the investigators stratified the surgical outcomes by pathology, the FLAIR-to-enhancing ratio trended differently between radiation necrosis and recurrent tumor, and patients who developed radiation necrosis had significantly lower FLAIR volumes at six weeks compared with those whose lesions harbored recurrent tumor.

This finding carries a counterintuitive implication. Clinicians often assume that more edema signals more trouble, and in the context of symptomatic mass effect that intuition holds. But the data suggest the opposite relationship for diagnostic purposes: a lesion that retains relatively little FLAIR hyperintensity six weeks after radiosurgery, despite failing to shrink, is more likely to be radiation necrosis, whereas a non-responding lesion wrapped in substantial and persistent edema raises greater concern for viable, actively growing tumor. The biological rationale is plausible. Radiation necrosis is fundamentally a vascular and inflammatory process driven by endothelial injury, blood-brain barrier disruption, and cytokine-mediated swelling, whereas recurrent tumor generates edema through tumor-cell infiltration, angiogenic signaling, and active secretion of vascular permeability factors. The two processes stamp different volumetric signatures on the surrounding brain, and the early post-treatment window appears to be when those signatures are most distinguishable.

Beyond the diagnostic ratios, the study identified which patient and lesion characteristics shape the edema trajectory itself. Linear mixed-effects models, a statistical framework well suited to repeated measurements nested within individual patients, showed that baseline lesion size, baseline FLAIR volume, and the FLAIR-to-enhancing ratio all influenced FLAIR trajectories with p-values below 0.001. Primary cancer type and sex also emerged as significant factors, each with p-values of 0.02. These results echo a growing body of literature indicating that peritumoral edema after radiosurgery is not a uniform phenomenon but one modulated by tumor histology, systemic therapy exposure, and intrinsic lesion characteristics. Larger lesions and those with greater baseline edema burdens follow different swelling curves than small, dry lesions, which means that any future edema-based diagnostic criterion will likely need to be normalized to baseline values rather than applied as an absolute threshold.

The clinical context makes the stakes of this work concrete. Stereotactic radiosurgery has become a cornerstone of brain metastasis management precisely because it delivers ablative doses of radiation with submillimeter accuracy while sparing surrounding tissue, allowing many patients to avoid whole-brain radiation and its cognitive sequelae. But local failure rates remain nontrivial, and a meaningful fraction of patients with non-responding lesions eventually come to surgery. Prior biopsy series have shown that enlarging lesions after radiosurgery frequently turn out to be radiation necrosis rather than tumor, which means that a substantial number of patients may currently undergo resection, or receive escalating systemic therapy, for a process that was never malignant. Conversely, misattributing recurrent tumor to necrosis delays effective treatment in a population where every month of uncontrolled intracranial disease matters. Any imaging tool that sharpens this fork in the road has immediate utility.

The Yale team’s methodological choices deserve attention because they point toward how such a tool could be deployed at scale. Manual segmentation of FLAIR hyperintensity is labor-intensive and subject to interobserver variability, which has historically limited edema volumetry to research settings. The authors explicitly recommend that automated edema volumetry be incorporated into routine post-SRS surveillance, and their proposal aligns with recent pilot work demonstrating that picture archiving and communication system-integrated volumetric tools can provide peritumoral edema measurements that add information beyond standard response assessment criteria for brain metastases. If FLAIR volume trajectories can be generated automatically at each surveillance scan, the six-week and three-month ratios identified in this study could become practical decision-support metrics, flagging non-responding lesions whose edema behavior suggests recurrent tumor for earlier tissue diagnosis or intensified imaging follow-up with advanced sequences such as perfusion and diffusion MRI.

The study’s limitations are those inherent to its design. Thirty-six patients from a single institution, all of whom underwent surgery and therefore represent the more severe end of the non-response spectrum, is a modest and selected sample. The pathological endpoint was available only for lesions that failed treatment, so the volumetric signatures of well-behaved responding lesions could not be compared against a full spectrum of outcomes. The authors also note that edema trajectories are variable across patients, and the FLAIR-to-enhancing ratio trended, rather than decisively separated, the two pathological groups at all time points, with the significant six-week FLAIR volume difference being the clearest single discriminator. Validation in larger, multi-institutional cohorts, ideally with prospective edema volumetry and standardized imaging protocols, will be essential before these thresholds inform treatment decisions.

Even so, the study adds a deceptively simple idea to the post-radiosurgery toolkit: the brain around the tumor is talking, and clinicians should start listening to it quantitatively. For two decades, surveillance after radiosurgery has centered on the enhancing lesion, with edema assessed qualitatively, if at all. This analysis demonstrates that perilesional FLAIR volume follows measurable, statistically characterizable trajectories that correlate with the enhancing compartment early after treatment and diverge in diagnostically informative ways when treatment fails. As automated segmentation matures and is folded into routine radiology workflows, the humble edema measurement that radiologists have long eyeballed as background noise may become one of the most actionable numbers on the post-radiosurgery scan, helping to spare patients with radiation necrosis from unnecessary surgery while accelerating definitive intervention for those whose tumors have truly returned.

Subject of Research: Volumetric MRI analysis of edema and enhancement changes after stereotactic radiosurgery for non-responding brain metastases

Article Title: Volumetric analysis of radiographic changes after stereotactic radiosurgery for treatment of non-responding brain metastases

Article References: Rajkumar, S., Moy, H., Ji, X., Aboian, M., & Chiang, V. (2026). Volumetric analysis of radiographic changes after stereotactic radiosurgery for treatment of non-responding brain metastases. Journal of Neuro-Oncology, 180(1), Article 7. https://doi.org/10.1007/s11060-026-05824-9

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05824-9

Keywords: stereotactic radiosurgery, brain metastases, radiation necrosis, FLAIR volumetry, perilesional edema, Gamma Knife, MRI surveillance, tumor recurrence, neuro-oncology, volumetric analysis, Journal of Neuro-Oncology, Volumetric

The research team, led by Florian Scheichel of University Hospital St. Pölten with colleagues from the Medical University of Innsbruck and Kepler University Hospital in Linz, confronted a methodological puzzle that has plagued the field for decades. Almost all existing data on steroid response in primary CNS lymphoma come from retrospective series with wildly inconsistent information about steroid dose, duration, and timing. In those studies, patients received steroids before their diagnostic imaging for variable reasons, and the intervals between scans and drug administration were uncontrolled. Some patients may have already regressed before their first scan; others may have progressed after an initial regression that nobody captured. The result was a literature in which reported response rates ranged from nearly ninety percent of tumors showing no change to nearly sixty percent showing progression, numbers so divergent that no reliable picture of steroid sensitivity could be drawn. The Austrian group designed their study to break this cycle by exploiting a window that every patient passes through but that had never been systematically imaged: the days immediately after biopsy, when the diagnosis is already secured and steroids are given routinely for symptom relief.

The prospective design was elegant in its simplicity. Patients with suspected primary large B-cell lymphoma of the central nervous system, who were scheduled for stereotactic or endoscopic biopsy at three Austrian neurosurgical centers, were enrolled after informed consent. Patients with systemic lymphoma, immunocompromise, or Epstein-Barr virus positivity were excluded, and the final diagnosis had to be confirmed as primary large B-cell CNS lymphoma. After surgery, all centers administered a comparable steroid protocol: an initial bolus of 40 milligrams of dexamethasone, followed by 16 milligrams daily, with the dose halved every three days. Critically, the team planned an additional thin-slice MRI five to ten days after surgery, timed to compare directly with the preoperative navigational MRI used to plan the biopsy. Patients were excluded if that second scan would have delayed definitive cancer treatment, a safeguard that cost the study thirteen of its forty screened candidates but protected the integrity of the remaining data. Eighteen patients formed the prospective volumetric cohort, ten women and eight men, none of whom suffered surgical complications that would have confounded the volume measurements.

The volumetric analysis was performed with 3D Slicer, an open-source platform for medical image computing, by segmenting the contrast-enhancing lesion on both the preoperative and post-steroid scans and calculating relative volume change. The results revealed a spectrum of behavior far wider than the word regression suggests. In 83.3 percent of cases the tumor shrank after steroids, with a median volume reduction of 40 percent, but the individual responses ranged from a barely perceptible one percent shrinkage to a dramatic 77 percent collapse. Meanwhile, in 16.7 percent of patients, the tumor did something counterintuitive: it grew despite the steroid therapy, with a median progression of 46 percent and one case expanding by 94 percent. Mean tumor volume fell from 16.1 cubic centimeters before surgery to 11.9 cubic centimeters after steroids across the cohort. The median interval between scans was seven days, and the median cumulative postoperative dexamethasone dose was 112 milligrams, with nearly all patients receiving between 104 and 140 milligrams.

Perhaps the most clinically consequential negative finding was what did not explain this heterogeneity. The researchers tested whether the degree of tumor volume change correlated with the cumulative steroid dose, the dose normalized to body surface area, or the duration of therapy, and found no evidence for any of these relationships. The Kendall-tau correlation between volume change and cumulative dose was a negligible 0.072 with a p-value of 0.694, and duration fared no better. In other words, a tumor that melted away under a standard steroid taper was not simply receiving more drug than one that expanded; the difference appears to reside in the biology of the malignant clone itself. There was, however, a suggestive signal involving lactate dehydrogenase, or LDH, the serum enzyme long known to be an adverse prognostic marker in both systemic lymphomas and primary CNS lymphoma. In the prospective cohort, higher preoperative LDH levels showed a trend toward correlation with worse radiological response, and when the analysis was expanded to a combined cohort of 31 patients, that correlation became statistically significant, with higher LDH predicting less tumor shrinkage on two-dimensional measurement.

That combined cohort was the study’s second analytical layer. Because eighteen patients were too few for meaningful survival statistics, the team merged their prospective data with a carefully filtered retrospective cohort of thirteen patients from their own earlier 2021 multicenter study. The inclusion criteria were strict: retrospective patients needed at least two preoperative MRI scans with steroid therapy initiated no more than two days before the first scan and continuing or uninterrupted between scans, ensuring that any observed change genuinely reflected the drug’s effect rather than uncontrolled timing. For this combined group, response was quantified as the change in the largest cross-sectional tumor area on an axial MRI slice, a two-dimensional measure that was validated against the volumetric results in the prospective patients with an intraclass correlation coefficient of 0.87, indicating excellent agreement between the two methods. In the combined cohort, 74.2 percent of tumors regressed and 25.8 percent progressed, and the two groups proved comparable in age, tumor size, Karnofsky performance status, involvement of deep brain structures, and treatment type, meaning the response pattern was not simply a proxy for having a bigger or more advanced tumor.

The survival analysis delivered the study’s headline result. Patients whose tumors regressed after steroids had a median overall survival of 31.4 months, while those whose tumors progressed despite steroids survived a median of just 3.9 months, a difference that reached statistical significance in Kaplan-Meier analysis with a p-value of 0.015. A sensitivity analysis excluding the three patients who had received steroids before biopsy preserved the finding, and a stratification using RECIST-style thresholds, at least 30 percent regression, stable disease, or at least 20 percent progression, showed a consistent trend, with median survival not reached in the regression group, 11.1 months for stable disease, and 3.9 months for progression. The authors then turned to Firth-corrected Cox regression, a statistical method designed for small samples with few events, and built a multivariable model including radiological response, age, Karnofsky performance status, and whether induction therapy contained high-dose methotrexate. In that model, tumor progression despite steroids carried a hazard ratio of 3.37 for death, with a p-value of 0.02 and a 95 percent confidence interval of 1.21 to 9.35, suggesting that radiological response is an independent prognostic factor rather than a mere echo of known predictors.

The biological interpretation is where the finding becomes genuinely provocative. Corticosteroids kill lymphoid cells through glucocorticoid receptor-mediated apoptotic pathways, and the sensitivity of a given lymphoma to this mechanism may reflect broader properties of drug responsiveness in the malignant clone. If a tumor cannot be pushed into apoptosis by a potent glucocorticoid, the reasoning goes, it may also respond poorly to methotrexate and the other cytotoxic agents that form the backbone of CNS lymphoma therapy. Progression despite steroids would then be a visible, early, and essentially free signal of multidrug resistance, available from scans that are already part of routine care. This would align with the rare but well-documented historic cases in which steroids alone produced prolonged, occasionally years-long remissions, presumably in patients with extreme intrinsic sensitivity. The authors are careful to frame their conclusions as exploratory: the sample was small, the survival analysis necessarily incorporated retrospective data, and confounders such as salvage therapies and treatment heterogeneity could not be fully controlled. Overall survival was chosen over progression-free survival precisely because follow-up strategies across centers were inconsistent.

The study also carries a practical warning that neurosurgeons and emergency physicians ignore at their patients’ peril. Preoperative steroids can render biopsies inconclusive, with histological disappearance of malignant B-cells reported in up to 52 percent of pretreated cases and threefold increases in non-diagnostic biopsies described in prior work. Guidelines therefore recommend avoiding steroids before tissue acquisition whenever clinically feasible, yet patients frequently arrive at specialized centers already steroid-treated because of neurological deterioration earlier in their pathway. The new data add a dimension to this dilemma: the same steroid exposure that risks obscuring the diagnosis may also, if properly documented with serial imaging, yield prognostic information that could eventually help stratify patients into risk-adapted treatment protocols. The Austrian team emphasizes that larger prospective multicenter studies are needed to validate the survival finding and to unravel the molecular mechanisms that determine why one patient’s lymphoma dissolves under dexamethasone while another’s grows through it. If those mechanisms can be identified, the humble steroid challenge, long viewed as a diagnostic nuisance, could be reframed as one of the cheapest prognostic tests in neuro-oncology.

Subject of Research: Radiological response of primary central nervous system lymphoma to corticosteroid therapy and its prognostic value for overall survival

Article Title: Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study

Article References: Scheichel, F., Pinggera, D., Rossmann, T., Popadic, B., Aspalter, S., Schön, V., Woehrer, A., Dorostkar, M. M., Dorfer, C., Freyschlag, C. F., & Marhold, F. (2026). Radiological response of primary central nervous system lymphoma after corticosteroid therapy and its predictive value on overall survival: a multicenter study. Journal of Neuro-Oncology, 179(2), Article 63. https://doi.org/10.1007/s11060-026-05773-3

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05773-3

Keywords: primary CNS lymphoma, corticosteroid therapy, MRI, overall survival, dexamethasone, lactate dehydrogenase, prognostic factors, volumetric analysis, methotrexate, neuro-oncology, Kaplan-Meier analysis, drug sensitivity